Switch to Elvitegravir-Cobicistat-Tenofovir DF-Emtricitabine

Study 123
Switch to Elvitegravir-Cobicistat-Tenofovir DF-Emtricitabine
Study 123: Study Design

• **Background**: Open-label, randomized phase 3b trial evaluating switching to once-daily elvitegravir-cobicistat-tenofovir DF-emtricitabine from twice daily raltegravir plus tenofovir DF-emtricitabine

• **Inclusion Criteria** (n = 48)
  - HIV RNA <50 copies/mL
  - On RAL+ TDF-FTC for ≥6 months
  - Not taking any other ART
  - No new AIDS-defining conditions

• **Treatment Arms**
  - Switch to EVG-COBI-TDF-FTC

Switch to Elvitegravir-Cobicistat-Tenofovir DF-Emtricitabine
Study 123: Results

Virologic Response After Switch to EVG-COBI-TDF-FTC

HIV RNA <50 copies/mL (%)

<table>
<thead>
<tr>
<th></th>
<th>Week 12</th>
<th>Week 24</th>
<th>Week 48</th>
</tr>
</thead>
<tbody>
<tr>
<td>100</td>
<td>48/48</td>
<td>48/48</td>
<td>48/48</td>
</tr>
</tbody>
</table>

**Switch to Elvitegravir-Cobicistat-Tenofovir DF-Emtricitabine**  
**Study 123: Common Adverse Events**

<table>
<thead>
<tr>
<th>Adverse Event (treatment emergent)</th>
<th>Switched to EVG-COBI-TDF-FTC (n = 48)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Upper Respiratory Tract Infection</td>
<td>21%</td>
</tr>
<tr>
<td>Insomnia</td>
<td>13%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>10%</td>
</tr>
<tr>
<td>Fatigue</td>
<td>10%</td>
</tr>
<tr>
<td>Anxiety</td>
<td>10%</td>
</tr>
</tbody>
</table>

Conclusion: “All participants switching to 1 tablet once-a-day elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (Stribild) from a twice-daily raltegravir + emtricitabine/tenofovir disoproxil fumarate regimen remained virologically suppressed. Stribild was well tolerated. Switching to Stribild may be a viable option for virologically suppressed patients wanting to simplify from a twice-daily raltegravir-containing regimen.”

The **National HIV Curriculum** is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling $1,021,448 with 0% financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit HRSA.gov. This project is led by the University of Washington’s Infectious Diseases Education and Assessment (IDEA) Program.